Acadia Pharmaceuticals (ACAD) Gross Margin (2016 - 2026)

Acadia Pharmaceuticals' Gross Margin history runs 11 years deep, the most recent figure standing at 90.75% for Q1 2026.

• In Q1 2026, Gross Margin fell 90.0% year-over-year to 90.75%; the TTM figure through Mar 2026 stood at 91.47% (down 57.0% YoY), while the FY2025 annual figure was 91.69%, up 24.0% from the prior year.
• Gross Margin for Q1 2026 stood at 90.75%, roughly flat from 90.77% in the prior quarter.
• The five-year high for Gross Margin was 98.59% in Q1 2023, with the low at 88.85% in Q1 2024.
• The 5-year median for Gross Margin is 92.47% (2024), against an average of 93.79%.
• The sharpest annual moves came in 2022 and 2024: Gross Margin surged 645 bps in 2022, then tumbled 974 bps in 2024.
• Acadia Pharmaceuticals' Gross Margin stood at 98.23% in 2022, then fell by 6 bps to 92.26% in 2023, then retreated by 1 bps to 91.6% in 2024, then declined by 1 bps to 90.77% in 2025, then dropped by 0 bps to 90.75% in 2026.
• Business Quant data shows ACAD's Gross Margin at 90.75% in Q1 2026, 90.77% in Q4 2025, and 92.23% in Q3 2025.